Jason  Lettmann net worth and biography

Jason Lettmann Biography and Net Worth

Director of ALX Oncology
Mr. Lettmann has served as a member of our board of directors since April 2020 and previously served as a member of our board of directors from March 2015 to May 2017. Mr. Lettmann has served as a General Partner of Lightstone Ventures since March 2012 and as a Partner at Morgenthaler Ventures, a venture capital and private equity firm, since June 2009. He previously served as Chief Executive Officer of Promedior Inc., a biotechnology company acquired by Roche, from January 2019 to February 2020 and as Vice President at Split Rock Partners, a venture capital firm, from June 2006 to June 2009. Mr. Lettmann currently serves as a member of the board of directors of several privately-held companies and previously served as a director of Ra Pharmaceuticals, a clinical-stage pharmaceutical company acquired by UCB. Mr. Lettmann holds a B.A. in Psychology from the University of Iowa and an M.B.A. from the University of Michigan’s Ross School of Business.

What is Jason Lettmann's net worth?

The estimated net worth of Jason Lettmann is at least $1.19 million as of March 14th, 2024. Mr. Lettmann owns 171,620 shares of ALX Oncology stock worth more than $1,189,327 as of June 19th. This net worth estimate does not reflect any other assets that Mr. Lettmann may own. Additionally, Mr. Lettmann receives a salary of $60,500.00 as Director at ALX Oncology. Learn More about Jason Lettmann's net worth.

How old is Jason Lettmann?

Mr. Lettmann is currently 47 years old. There are 4 older executives and no younger executives at ALX Oncology. The oldest executive at ALX Oncology is Dr. Corey S. Goodman Ph.D., Executive Chairman, who is 72 years old. Learn More on Jason Lettmann's age.

What is Jason Lettmann's salary?

As the Director of ALX Oncology Holdings Inc., Mr. Lettmann earns $60,500.00 per year. There are 5 executives that earn more than Mr. Lettmann. The highest earning executive at ALX Oncology is Dr. Jaume Pons Ph.D., Founder, President, Director & Chief Scientific Officer, who commands a salary of $856,290.00 per year. Learn More on Jason Lettmann's salary.

How do I contact Jason Lettmann?

The corporate mailing address for Mr. Lettmann and other ALX Oncology executives is 866 MALCOLM ROAD SUITE 100, BURLINGAME CA, 94010. ALX Oncology can also be reached via phone at 650-466-7125 and via email at [email protected]. Learn More on Jason Lettmann's contact information.

Has Jason Lettmann been buying or selling shares of ALX Oncology?

Jason Lettmann has not been actively trading shares of ALX Oncology within the last three months. Most recently, on Thursday, March 14th, Jason Lettmann bought 4,400 shares of ALX Oncology stock. The stock was acquired at an average cost of $11.31 per share, with a total value of $49,764.00. Following the completion of the transaction, the chief executive officer now directly owns 171,620 shares of the company's stock, valued at $1,941,022.20. Learn More on Jason Lettmann's trading history.

Who are ALX Oncology's active insiders?

ALX Oncology's insider roster includes Peter Garcia (CFO), Jason Lettmann (Director), Jaume Pons (CEO), and Sophia Randolph (Insider). Learn More on ALX Oncology's active insiders.

Are insiders buying or selling shares of ALX Oncology?

In the last twelve months, ALX Oncology insiders bought shares 2 times. They purchased a total of 16,400 shares worth more than $152,124.00. In the last twelve months, insiders at the sold shares 11 times. They sold a total of 138,228 shares worth more than $1,741,379.04. The most recent insider tranaction occured on June, 13th when CFO Peter S Garcia bought 12,000 shares worth more than $102,360.00. Insiders at ALX Oncology own 33.4% of the company. Learn More about insider trades at ALX Oncology.

Information on this page was last updated on 6/13/2024.

Jason Lettmann Insider Trading History at ALX Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2024Buy4,400$11.31$49,764.00171,620View SEC Filing Icon  
12/13/2021Sell325,377$27.36$8,902,314.72View SEC Filing Icon  
12/9/2021Sell76,905$32.03$2,463,267.15View SEC Filing Icon  
See Full Table

Jason Lettmann Buying and Selling Activity at ALX Oncology

This chart shows Jason Lettmann's buying and selling at ALX Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ALX Oncology Company Overview

ALX Oncology logo
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $6.93
Low: $6.81
High: $7.46

50 Day Range

MA: $13.16
Low: $6.93
High: $17.56

2 Week Range

Now: $6.93
Low: $3.94
High: $17.83


946,776 shs

Average Volume

921,696 shs

Market Capitalization

$361.05 million

P/E Ratio


Dividend Yield